Patrick Hopen, MD
Ophthalmology · Indianapolis, INNPI 1548585854
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,469 and has fallen 69.8% since, to $746 in 2025. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $34.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lensar, Inc.$2K
- Glaukos Corporation$2K
- Alcon$1K
- AbbVie$1K
- Rxsight Inc$416
- Novartis$361
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$5246%
- Food & beverage$7,76694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lensar, Inc. | 20 | $1,927 |
| Glaukos Corporation | 30 | $1,747 |
| Alcon | 47 | $1,263 |
| AbbVie(2 entities) | 53 | $1,140 |
| Rxsight Inc | 16 | $416 |
| Novartis | 16 | $361 |
| Bausch & Lomb Americas Inc. | 9 | $193 |
| Dompe US, Inc. | 4 | $180 |
| Sight Sciences, Inc. | 3 | $162 |
| Apellis Pharmaceuticals, Inc. | 2 | $137 |
| NEW World Medical,inc. | 7 | $128 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $115 |
| Ivantis, Inc | 3 | $99 |
| Ocular Therapeutix, Inc. | 5 | $89 |
| Thea Pharma Inc. | 3 | $63 |
| Biotissue Holdings Inc. | 2 | $47 |
| Harrow Eye, LLC | 2 | $44 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Beaver-visitec International, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
| Oyster Point Pharma, Inc. | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$1,629
- iStent infinite Trabecular Micro-Bypass System Model iS3$345
- iStent Trabecular Micro-Bypass System Model iS3$332
- RADIUS$302
- Hydrus Microstent$260
- DURYSTA$224
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$173
- LUMIGAN$150
- iDose$146
- OMNI(R) SURGICAL SYSTEM (US)$130
- Clareon$129
- Oxervate$124
- Syfovre$124
- RXSIGHT CONTACT LENS$115
- RXSIGHT INJECTOR CARTRIDGE$115
- RXSIGHT INJECTOR HANDPIECE$115
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$115
- LIGHT ADJUSTABLE LENS (LAL)$115
How this compares
$8,289 in reported general payments places this provider in the 90th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 41 | $17,493 |
| RestasisCyclosporine | 17 | $15,093 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $14,993 |
| RocklatanNetarsudil Mesylat/Latanoprost | 33 | $12,044 |
| VyzultaLatanoprostene Bunod | 16 | $7,797 |
| Prednisolone Acetate | 154 | $7,731 |
| Ketorolac Tromethamine | 239 | $6,316 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $5,047 |
| Latanoprost | 380 | $3,586 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 141 | $1,814 |
| MoxifloxacinMoxifloxacin Hcl | 44 | $1,302 |
| Ofloxacin | 74 | $1,295 |
| Brimonidine Tartrate | 49 | $637 |
| Diclofenac Sodium | 46 | $554 |
| Timolol Maleate | 59 | $388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $1,140 | $47,58092 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $193 | $7,79716 claims |
| AlconSimbrinza | $1,263 | $5,04721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
- John LindIndianapolis$20K
- Shaohui LiuIndianapolis$19K
- John LatonaIndianapolis$18K
- William WhitsonIndianapolis$15K
- Thierry WilbrandtIndianapolis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.